Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks
Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
Start Today
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //
Register
AdChoices
Today's Change
Volume
Real-Time Last Update TSX Last Sale
Alerts Watchlist Portfolio

Today's Trading

Day Low 5.39
Day High 5.59
Open:5.59
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Latest
inside the market
The week’s most oversold and overbought stocks on the TSX
Subscriber content
inside the market
Market movers: Stocks that saw action on Tuesday - and why
Subscriber content
inside the market
Tuesday’s small-cap stocks to watch
Subscriber content
inside the market
The week’s most oversold and overbought stocks on the TSX
Subscriber content
inside the market
The week’s most oversold and overbought stocks on the TSX
Subscriber content
inside the market
Tuesday’s small-cap stocks to watch
Subscriber content
Description
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

View Earnings

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

View Estimates zacks

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

Download Premium PDF Refinitiv. Trademark. Data is Just the Beginning.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

Download Premium PDF StockCalc

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Download Free PDF ValueEngine logo

Latest Press Releases

More Stories
Knight Therapeutics Reports Third Quarter 2020 Results
- GlobeNewswire - Fri Nov 13, 6:30AM CST
GlobeNewswire - CMTX
Fri Nov 13, 6:30AM CST
Knight Therapeutics Inc. (TSX: GUD) ("Knight" or "the Company"), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2020. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified.
Notice of Knight Therapeutics' Third Quarter 2020 Results Conference Call
- GlobeNewswire - Fri Nov 6, 6:30AM CST
GlobeNewswire - CMTX
Fri Nov 6, 6:30AM CST
Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2020 financial results on Friday, November 13, 2020 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.
Knight Signs New Exclusive AmBisome(R) Agreement with Gilead in Brazil
- GlobeNewswire - Mon Oct 26, 6:30AM CDT
GlobeNewswire - CMTX
Mon Oct 26, 6:30AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, today announced the signing of a new exclusive distribution agreement with Gilead Sciences, Inc. ("Gilead") for the commercialization of AmBisome(R) (liposomal amphotericin B) in Brazil. The agreement will be effective starting January 1, 2021.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 5.23 +5.54% increase
on 11/16/20
Period Open:5.63
Price movement based on the high, low and last over the given period.
5.85 -5.64% decrease
on 11/09/20
 -0.11 (-1.95%) decrease
since 10/27/20
3-Month 5.23 +5.54% increase
on 11/16/20
Period Open:6.41
Price movement based on the high, low and last over the given period.
6.48 -14.81% decrease
on 08/28/20
 -0.89 (-13.88%) decrease
since 08/27/20
52-Week 4.73 +16.70% increase
on 03/19/20
Period Open:7.64
Price movement based on the high, low and last over the given period.
8.12 -32.02% decrease
on 01/16/20
 -2.12 (-27.75%) decrease
since 11/27/19

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies